Further insight into the cardiovascular risk calculator: The roles of statins, revascularizations, and underascertainment in Thewomen's health study

JAMA Internal Medicine

Volumn 174, Issue 12, 2014, Pages 1964-1971

  Cook, Nancy R ^a,b   Ridker, Paul ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; ASCERTAINMENT BIAS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SENSITIVITY ANALYSIS; WOMEN'S HEALTH; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DEATH; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRESCRIPTION; RISK FACTOR; STATISTICS AND NUMERICAL DATA; STROKE; UNITED STATES;

AGED; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; DEATH; DRUG PRESCRIPTIONS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; RISK ASSESSMENT; RISK FACTORS; STROKE; UNITED STATES; WOMEN'S HEALTH;

EID: 84919472128     PISSN: 21686106     EISSN: 21686114     Source Type: Journal    
DOI: 10.1001/jamainternmed.2014.5336     Document Type: Article

References (23)

1. Goff DC Jr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25)(suppl 2):S49-S73.
2. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women, 2011 update: a guideline from the American Heart Association. Circulation. 2011;123(11):1243-1262.
3. Ridker PM, Cook NR. Statins: new American guidelines for prevention of cardiovascular disease. Lancet. 2013;382(9907):1762-1765.
4. Kavousi M, Leening MJG, Nanchen D, et al. Comparison of application of the ACC/AHA guidelines, Adult Treatment Panel III guidelines, and European Society of Cardiology guidelines for cardiovascular disease prevention in a European cohort. JAMA. 2014;311(14):1416-1423.
5. Muntner P, Colantonio LD, Cushman M, et al. Validation of the atherosclerotic cardiovascular disease pooled cohort risk equations. JAMA. 2014;311(14):1406-1415.
6. Lloyd-Jones DM, Goff D, Stone NJ. Statins, risk assessment, and the new American prevention guidelines. Lancet. 2014;383(9917):600-602.
7. Muntner P, Safford MM, Cushman M, Howard G. Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129(2):266-267.
8. Cook NR, Ridker PM. Response to Comment on the reports of over-estimation of ASCVD risk using the 2013 AHA/ACC risk equation. Circulation. 2014;129(2):268-269.
9. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293-1304.
10. Lee IM, Cook NR, Gaziano JM, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: theWomen's Health Study: a randomized controlled trial. JAMA. 2005;294(1):56-65.
11. Sesso HD, Gaziano JM, Glynn RJ, Buring JE. Value of an Endpoints Committee versus the use of nosologists for validating cause of death. Contemp Clin Trials. 2006;27(4):333-339.
12. Mihaylova B, Emberson J, Blackwell L, et al; Cholesterol Treatment Trialists' (CTT) Collaborators. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581-590.
13. Pursnani S, Korley F, Gopaul R, et al. Percutaneous coronary intervention versus optimal medical therapy in stable coronary artery disease: a systematic review and meta-analysis of randomized clinical trials. Circ Cardiovasc Interv.2012;5(4):476-490.
14. Rexrode KM, Lee IM, Cook NR, Hennekens CH, Buring JE. Baseline characteristics of participants in theWomen's Health Study. JWomens Health Gend Based Med. 2000;9(1):19-27.
15. Colditz GA, Martin P, Stampfer MJ, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123(5):894-900.
16. Liu S, Lee I-M, Song Y, et al. Vitamin E and risk of type 2 diabetes in the women's health study randomized controlled trial. Diabetes. 2006;55(10):2856-2862.
17. Ridker PM, Buring JE, Rifai N, Cook NR. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds risk score. JAMA. 2007;297(6):611-619.
18. Ridker PM, Paynter NP, Rifai N, Gaziano JM, Cook NR. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds risk score for men. Circulation. 2008;118(22):2243-2251.
19. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl JMed. 2007;356(23):2388-2398.
20. Gregg EW, Li Y,Wang J, et al. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370(16):1514-1523.
21. D'Agostino RB Sr. Understanding the cardiovascular disease risk functions: aim, development, and evaluation. N Engl J Med. 2014;370(17):1652-1653.
22. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25)(suppl 2):S1-S45.
23. MyersonM, Coady S, Taylor H, Rosamond WD, Goff DCJ Jr; ARIC Investigators. Declining severity ofmyocardial infarction from 1987 to 2002: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2009;119(4):503-514.